Supported by the Industrial Development Authority (IDA) of Ireland, the €40m expansion is likely to be continued for a period of four years.
The expansion plan takes the firm’s total investment in Ballytivnan and broader manufacturing operations in the country to over €134m since 2013.
This investment is aimed at a production increase for AbbVie’s drug delivery devices from the site, which manufactures a pen-style injector used for treatment of auto-immune conditions worldwide.
AbbVie Ballytivnan site director Joe Kumor said: "The IDA’s support allows us to build our capabilities and help ensure that patients of AbbVie medicines continue to have access to best-in-class medical devices for their treatment."
The company intends to add 50 new highly-skilled jobs as part of the expansion plan.
Along with the development of the global medical device centre in the Irish town, AbbVie will also form a partnership with the Institute of Technology in Sligo.
Institute of Technology, Sligo president professor Vincent Cunnane said: "Working with AbbVie or other external partners on our curricula make them highly attractive for graduates.
"Together with these types of partnerships, we are also growing Sligo’s presence and reputation in the IT and medical device fields, which ultimately benefits the people of Sligo."
Image: The €40m investment is aimed at strengthening AbbVie’s drug delivery devices from the site. Photo: courtesy of dream designs / FreeDigitalPhotos.net.
